Nebulized Tyvaso — Gross Profit
United Therapeutics Nebulized Tyvaso — Gross Profit decreased by 0.6% to $118.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 23.6%, from $155.30M to $118.60M. Over 3 years (FY 2021 to FY 2025), Nebulized Tyvaso — Gross Profit shows relatively stable performance with a -1.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase reflects improved pricing power, lower production costs, or higher sales volume, signaling strong product-level profitability.
Detailed definition
This metric represents the residual profit after deducting the direct cost of sales from the total revenue generated by...
Peer comparison
Comparable to segment-level gross profit metrics reported by other pharmaceutical companies with diversified drug portfolios.
uthr_segment_nebulized_tyvaso_gross_profitHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $145.18M | $145.18M | $145.18M | $187.90M | $113.50M | $117.90M | $110.90M | $127.90M | $136.10M | $131.50M | $149.80M | $135.30M | $155.30M | $148.80M | $135.10M | $119.30M | $118.60M |
| QoQ Change | — | +0.0% | +0.0% | +29.4% | -39.6% | +3.9% | -5.9% | +15.3% | +6.4% | -3.4% | +13.9% | -9.7% | +14.8% | -4.2% | -9.2% | -11.7% | -0.6% |
| YoY Change | — | — | — | +29.4% | — | — | -41.0% | — | +19.9% | +11.5% | +35.1% | +5.8% | +14.1% | +13.2% | -9.8% | -11.8% | -23.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's nebulized tyvaso — gross profit?
- United Therapeutics (UTHR) reported nebulized tyvaso — gross profit of $118.60M in Q1 2026.
- How has United Therapeutics's nebulized tyvaso — gross profit changed year-over-year?
- United Therapeutics's nebulized tyvaso — gross profit decreased by 23.6% year-over-year, from $155.30M to $118.60M.
- What is the long-term trend for United Therapeutics's nebulized tyvaso — gross profit?
- Over 3 years (2021 to 2025), United Therapeutics's nebulized tyvaso — gross profit has grown at a -1.3% compound annual growth rate (CAGR), from $580.70M to $558.50M.
- What does nebulized tyvaso — gross profit mean?
- The profit remaining from the nebulized drug sales after accounting for the direct costs of production.